Peptide comparisons
29 side-by-side breakdowns, each with a plain-English verdict on which to pick and why. No hedging, the actual call.
Not sure which two to compare?
Tell the AI Coach your goal โ fat loss, recovery, muscle, longevity โ and it lines up the right compounds for you and walks through the trade-offs. Free.
GH-axis
Ipamorelin tells the pituitary to fire a GH pulse; CJC-1295 (no DAC) makes each pulse bigger by mimicking GHRH.
The real split is oral versus injection.
HGH is the actual growth hormone, injected directly, which makes it the strongest lever and also the highest legal-risk compound in this space.
HGH is the hormone itself, injected, and it carries the heaviest legal risk in this catalog.
Both raise GH but from different angles.
Same mechanism (both are GHRH analogs), different weight class.
Both are GHRH analogs that restore natural GH pulses; the difference is in the molecule's stability.
Power versus cleanliness.
Two IGF-1 variants tuned for different reach.
HGH is the hormone itself, injected directly, the strongest GH lever and the highest legal-risk compound in this catalog.
Fat Loss
Tirzepatide hits two receptors (GLP-1 plus GIP) where Semaglutide hits one, and in head-to-head trials that second lever shows up as more weight lost on average and, for a lot of people, less gut nausea per pound dropped.
Retatrutide adds a third receptor (glucagon) on top of the GLP-1 and GIP that Tirzepatide already covers, and its trial numbers are the largest weight-loss figures anyone has published for this class.
Semaglutide works the GLP-1 satiety pathway; Cagrilintide works the amylin pathway.
Same family, different reach: Tirzepatide is a dual agonist (GLP-1 + GIP), Retatrutide is a triple (it adds glucagon).
This is the biggest generational gap in the GLP-1 space.
Two separate hunger switches.
These are close cousins, both come from the fat-loss tail of the HGH molecule and aim to trigger lipolysis without the full growth-hormone side effects.
Same drug class, different developers and timelines.
Semaglutide is the global GLP-1 standard, single-receptor, fully FDA-approved, years of real-world use.